Exercise program to slow prostate cancer progression in Black men

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This research focuses on a 16-week, home-based, virtually supervised exercise program aimed at Black men with early-stage prostate cancer who are on active surveillance. Participants will be randomly assigned to either an aerobic high-intensity interval training (HIIT) group or a usual care group. The study aims to assess whether this exercise intervention can effectively slow cancer progression, addressing a significant gap in research involving Black men, who are at a higher risk for progression. The study will include eligibility screenings, treatment visits, and follow-up assessments over approximately 18 weeks.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥18 years.
* Histologically diagnosed with localized prostate cancer.
* Initiating or undergoing active surveillance.
* Having a higher risk of progression, defined as meeting one or more of the following: (1) favorable- intermediate risk prostate tumor at diagnosis, (2) obesity (body mass index ≥ 30), and/or (3) self- identified as Black or African American.
* No plans for invasive treatment for their prostate cancer in the 12 weeks following the time of enrollment.
* Ability to understand and willingness to provide informed consent.

Exclusion Criteria:

* Received any invasive curative-intent treatment for prostate cancer, including surgery, chemotherapy, radiation therapy, and hormonal therapy.
* Patients with metastasis and/or other active malignancies (except basal cell carcinoma) and/or receiving treatment for those malignancies.
* Participating in any (\>0 min/week) high-intensity exercise at the time of recruitment.
* Having chronic medical conditions that are clinically unstable or uncontrolled with medications, deemed high-risk for exercise. These include but are not limited to unstable cardiac diseases, uncontrolled diabetes, and bone metastases with imminent risk of fracture.
* Having a high risk for noncompliance with study procedures. This will be determined by the study team based on the history of missed oncology appointments (i.e., ≥3 no-shows in 6 months) and poor responsiveness during recruitment (i.e., ≥3 unreturned contacts).
* Patients who are non-English speaking and unable to complete the participant surveys.

Where it's running

• Fred Hutch/University of Washington Cancer Consortium
  Seattle, Washington, United States Recruiting
• Beth Israel Deaconess Medical Center
  Boston, Massachusetts, United States Completed
• Brigham and Women's Hospital
  Boston, Massachusetts, United States Completed
• Dana-Farber Cancer Institute
  Boston, Massachusetts, United States Completed

Study contacts

• Principal investigator: Dong-Woo Kang, PhD — Fred Hutch/University of Washington Cancer Consortium
• Study coordinator: Dong-Woo Kang, PhD
• Email: dkang@fredhutch.org
• Phone: 206-667-5188

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer

  This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.

  Recruiting Lithuanian University of Health Sciences · Kaunas · NCT07863986

• Shorter Salvage Radiotherapy after Prostate Surgery for Recurrent Prostate Cancer

  This study tests whether a shorter, 4-week salvage radiotherapy schedule is as safe and effective as the standard 5-week schedule for men with prostate cancer that has come back after surgery.

  Recruiting CHU de Quebec-Universite Laval · Gatineau, Quebec and 3 other locations · NCT07483658

• PSMA PET/CT plus MRI to find higher‑grade prostate cancer in men on active surveillance

  This study tries adding rhPSMA-7.3 (flotufolastat F18) PET/CT to standard mpMRI to see if it finds higher-grade prostate cancer in men on active surveillance.

  Recruiting Phase 2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT07285057

• New treatment for metastatic prostate cancer using ifinatamab deruxtecan

  This study is testing a new treatment called ifinatamab deruxtecan to see if it helps men with advanced prostate cancer live longer and feel better compared to standard chemotherapy.

  Recruiting at 290 sites Phase 3 Merck Sharp & Dohme LLC · Phoenix, Arizona and 302 other locations · NCT06925737

• Using a new type of PET scanner for imaging prostate cancer and related conditions

  This study is testing a new type of PET scanner to see if it can better detect early signs of prostate cancer and related conditions in patients.

  Recruiting Jagiellonian University · Krakow · NCT06242119

• Using 64Cu-SAR-bisPSMA PET to detect prostate cancer spread before surgery

  This study is testing a new imaging method to see if it can help find prostate cancer spread in high-risk patients before they have surgery.

  Recruiting at 34 sites Phase 3 Clarity Pharmaceuticals Ltd · Birmingham, Alabama and 33 other locations · NCT06056830

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.